Posts in category

In Depth


Pharmacists are being warned that a long-time ally “may soon be turned into an enemy”, through the creation of a government-backed monopoly  It’s 1949 and the Australasian Journal of Pharmacy …

Hi, I’m your pharmacist and I’m not ignoring you it’s just that I’m pretty focused on my job at the moment  Although you may not really understand all that this …

Debbie Rigby rounds up the latest in research news Respiratory syncytial virus in children Respiratory syncytial virus (RSV) is one of the most common causes of lower respiratory tract infection …

Over six months have passed since the implementation of sixty-day dispensing. It’s time to start monitoring your pharmacy’s performance during the transition, says Victoria Le In a recent LinkedIn video, …

An impersonation scandal, the fate of “Rat Biskett” and some tips on opium for smoking all made the news in April 1904 That month, we reported on a special meeting …

Why pharmacists are a critical part of the aged care puzzle, say Fei Sim and Laetitia Hattingh With Australia’s ageing population and increased healthcare needs, the seamless transition between hospital, …

Debbie Rigby rounds up the latest in research news Embedded on-site aged care pharmacists in Australia This study highlights the resident- and system-level roles and benefits of embedded on-site pharmacists, …

Pharmacy owners must make sure that their space investment works well, but are they stocking the right categories to maximise their returns? Bermuda is a British overseas territory in the …

Risk factors for overdose are surprisingly common among patients taking prescribed opioids, but how can pharmacists best approach conversations around safety and prevention? Sheshtyn Paola investigates  Most people know that …

To everything there is a season, the AJP wrote in 1964 – as the season of weighing up professional quality against price came around again W.R.Cutler wrote a guest editorial …

We look at some of the recent changes to the medicines landscape, with new products, indications and contraindications New Products Fezolinetant (Veoza) is a nonhormonal selective NK3 receptor antagonist that …

Evidence is growing that some institutional advisors may be starting to grow wary of the CWH/Sigma deal, says Mike Taylor   When financial advisers make investment recommendations to clients they are …